<?xml version='1.0' encoding='utf-8'?>
<document id="17019057"><sentence text="Clinical oral doses of dexamethasone decreases intrinsic clearance of quinidine, a cytochrome P450 3A substrate in dogs."><entity charOffset="23-36" id="DDI-PubMed.17019057.s1.e0" text="dexamethasone" /><entity charOffset="70-79" id="DDI-PubMed.17019057.s1.e1" text="quinidine" /><pair ddi="false" e1="DDI-PubMed.17019057.s1.e0" e2="DDI-PubMed.17019057.s1.e0" /><pair ddi="false" e1="DDI-PubMed.17019057.s1.e0" e2="DDI-PubMed.17019057.s1.e1" /></sentence><sentence text="We investigated the effect of dexamethasone (DEX) at clinical doses on the pharmacokinetics of quinidine (QN) in dogs"><entity charOffset="30-43" id="DDI-PubMed.17019057.s2.e0" text="dexamethasone" /><entity charOffset="95-104" id="DDI-PubMed.17019057.s2.e1" text="quinidine" /><entity charOffset="106-108" id="DDI-PubMed.17019057.s2.e2" text="QN" /><pair ddi="false" e1="DDI-PubMed.17019057.s2.e0" e2="DDI-PubMed.17019057.s2.e0" /><pair ddi="false" e1="DDI-PubMed.17019057.s2.e0" e2="DDI-PubMed.17019057.s2.e1" /><pair ddi="false" e1="DDI-PubMed.17019057.s2.e0" e2="DDI-PubMed.17019057.s2.e2" /><pair ddi="false" e1="DDI-PubMed.17019057.s2.e1" e2="DDI-PubMed.17019057.s2.e1" /><pair ddi="false" e1="DDI-PubMed.17019057.s2.e1" e2="DDI-PubMed.17019057.s2.e2" /></sentence><sentence text=" Dogs (5 healthy 1-year-old male beagles) were orally administered DEX once daily for 5 days at 2" /><sentence text="5 or 7" /><sentence text="5 mg/day" /><sentence text=" QN (2 mg/kg) was intravenously injected 3 weeks before and one day after the DEX treatment"><entity charOffset="1-2" id="DDI-PubMed.17019057.s6.e0" text="QN" /></sentence><sentence text=" The plasma concentration of QN was determined by high-performance liquid chromatography with fluorometric detection"><entity charOffset="29-30" id="DDI-PubMed.17019057.s7.e0" text="QN" /></sentence><sentence text=" Plasma concentrations of albumin and alpha(1)-acid glycoprotein (AGP) were determined by a bromocresol green method and a single immunodiffusion method, respectively" /><sentence text=" In order to calculate unbound concentrations of QN in plasma, the binding kinetics of QN in plasma was examined by an ultrafiltration method using pooled plasma from the 5 dogs when they were drug-free"><entity charOffset="49-50" id="DDI-PubMed.17019057.s9.e0" text="QN" /><entity charOffset="87-88" id="DDI-PubMed.17019057.s9.e1" text="QN" /><pair ddi="false" e1="DDI-PubMed.17019057.s9.e0" e2="DDI-PubMed.17019057.s9.e0" /><pair ddi="false" e1="DDI-PubMed.17019057.s9.e0" e2="DDI-PubMed.17019057.s9.e1" /></sentence><sentence text=" Total body clearance of QN was decreased dose-dependently By the DEX treatment, although the decrease was not statistically significant"><entity charOffset="25-26" id="DDI-PubMed.17019057.s10.e0" text="QN" /></sentence><sentence text=" Elimination half-lives significantly increased (more than twice at 7" /><sentence text="5 mg), and intrinsic clearance significantly decreased (about 50%)" /><sentence text=" The volume of distribution increased significantly (about two-fold)" /><sentence text=" Plasma levels of AGP significantly decreased, and the unbound fraction of QN in plasma significantly increased"><entity charOffset="75-76" id="DDI-PubMed.17019057.s14.e0" text="QN" /></sentence><sentence text=" Our results demonstrate that clinical doses of DEX significantly affect the pharmacokinetics of QN, a CYP3A substrate in dogs, by decreasing CYP3A activity and plasma AGP levels"><entity charOffset="97-98" id="DDI-PubMed.17019057.s15.e0" text="QN" /></sentence><sentence text=" There is a possibility that adverse drug-drug interaction occurs during DEX therapy through its effects on CYP3A activity and plasma AGP levels" /><sentence text="" /></document>